ONCORADIOMICS

Their core work

Oncoradiomics is a Belgian SME specializing in radiomics — the extraction of quantitative features from medical images using AI and deep learning to support cancer diagnosis and treatment decisions. They develop decision support tools that translate complex imaging data (CT, MRI, PET) into actionable clinical insights for precision oncology. Their work spans the full pipeline from large-scale cancer image analysis and collaborative data annotation to AI-driven diagnostic platforms and therapeutic vaccine development. They operate at the intersection of medical imaging, artificial intelligence, and clinical oncology.

What they specialise in

How they've shifted over time

Oncoradiomics entered H2020 in 2017 through PREDICT, focused on establishing radiomics as a viable clinical tool for personalized diagnostics. From 2020 onward, their work shifted significantly — DRAGON and EuCanImage show a move toward large-scale AI platforms, regulatory frameworks (AI passport, in silico trials), and pandemic-responsive precision medicine. Most recently, TIGER (2021) signals a pivot toward therapeutic interventions with mRNA cancer vaccines, suggesting the company is expanding beyond diagnostics into treatment development.

Oncoradiomics is moving from pure diagnostic AI toward therapeutic applications and regulatory-ready AI frameworks, positioning themselves for clinical deployment rather than research alone.

How they like to work

Oncoradiomics participates exclusively as a partner, never as coordinator, which is typical for a specialized SME contributing deep technical expertise to larger consortia. With 60 unique partners across 13 countries in just 4 projects, they operate in large, multi-national consortia (averaging 15+ partners per project). This broad network suggests they are valued as a specialist contributor that integrates well into diverse teams rather than driving project direction.

Despite only 4 projects, Oncoradiomics has built a remarkably wide network of 60 unique partners across 13 countries, reflecting the large-consortium nature of EU health and AI projects. Their Belgian base and health-sector focus likely connect them strongly to Western European clinical research hubs.

What sets them apart

Oncoradiomics occupies a rare niche at the exact intersection of medical imaging AI and clinical oncology — a space where few SMEs have both the technical depth in radiomics and the clinical domain knowledge to deliver usable tools. Their progression from diagnostic radiomics to mRNA vaccine platforms shows unusual versatility for a small company, bridging computational and therapeutic oncology. For consortium builders, they bring specialized AI-for-cancer capability that is hard to source from generic AI companies or purely academic groups.

Highlights from their portfolio

• DRAGON
  Largest funding (EUR 1.73M) and broadest scope — combining pandemic management, AI diagnostics, and precision medicine in a single decision support framework.
• TIGER
  Represents a strategic pivot into mRNA cancer vaccines targeting HPV-related cancers, moving Oncoradiomics from diagnostics into therapeutic development.
• EuCanImage
  Addresses the critical infrastructure gap of a pan-European cancer imaging platform with AI governance standards (AI passport), positioning the company in regulatory conversations.